ArticleJournal of gastroenterology2020
Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Article in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Trial
- Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study.Drug safety · 2025Article
- Site-specific activation of the proton pump inhibitor rabeprazole by tetrathiolate zinc centres.Nature chemistry · 2025Article
- Maintenance proton pump inhibitor use and risk of colorectal cancer: a Swedish retrospective cohort study.BMJ open · 2024Article
- Duodenal and pancreatic tissue microbiome profiles of PPI users and non-users.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2024Article
- Appropriateness and inappropriate medication predictors of stress ulcer prophylaxis in the intensive care unit.Frontiers in pharmacology · 2024Article
- Proton pump inhibitors and risk of gastrointestinal cancer: A meta‑analysis of cohort studies.Oncology letters · 2024Article
- Long-Term Administration of Omeprazole-Induced Hypergastrinemia and Changed Glucose Homeostasis and Expression of Metabolism-Related Genes.BioMed research international · 2024Article
- Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.Digestive diseases and sciences · 2023Article
- Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.Chonnam medical journal · 2023Review
- Article
- Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study.Journal of clinical medicine · 2022Article
- Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Current practice of stress ulcer prophylaxis in a surgical patient cohort in a German university hospital.Langenbeck's archives of surgery · 2021Article
- Current Practice of Stress Ulcer Prophylaxis in Surgical Departments in Mecklenburg Western Pomerania, Germany.Healthcare (Basel, Switzerland) · 2021Article
- Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study.Journal of personalized medicine · 2021Article
- Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Proton pump inhibitors and the risk of pancreatic cancer.Journal of gastroenterology · 2021Article
Corrections and comments
- AssociatedDataset
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe long-term safety of proton pump inhibitors (PPIs) is increasingly questioned. The aim of our study was to assess the risk of pancreatic cancer among long-term PPI users in Sweden.
methodsThis population-based nationwide Swedish cohort study including 796,492 adult long-term PPI users has been used to calculate the standardized incidence rate ratios (SIRs) and 95% confidence intervals (CI) for pancreatic cancer, stratifying by indications of use, age, sex, and duration of use. The risk among all 20,210 long-term H2-receptor antagonist users was assessed as comparison.
resultsPancreatic cancer was found in 1733 long-term PPI users, and 25 H2-receptor antagonist users. For PPI users, the risk of pancreatic cancer was increased overall (SIRs = 2.22; 95% CI 2.12-2.32) and in all subgroup analyses, with the highest risk among PPI-users younger than 40 years (SIR = 8.90, 95% CI 4.26-16.37), and among individuals with a history of Helicobacter pylori (SIR = 2.99, 95% CI 2.54-3.49). After the first year after enrolment (during which PPI use may be because of early symptoms of pancreatic cancer), the risk remained increased over time, with SIR = 1.57 (95% CI 1.38-1.76) after 5 years. No associations were found for H2-receptor antagonists (SIR = 1.02, 95% CI 0.66-1.51).
conclusionsThis large study showed an increased risk of pancreatic cancer in long-term users of PPIs in Sweden, in particular among the youngest users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.